TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 156 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $30,061,363 | -13.8% | 1,957,120 | +26.2% | 0.04% | -18.2% |
| Q1 2023 | $34,870,790 | +298476.8% | 1,550,502 | +179.2% | 0.04% | +158.8% |
| Q4 2022 | $11,679 | -99.9% | 555,366 | +34.6% | 0.02% | +13.3% |
| Q3 2022 | $10,164,000 | +18.8% | 412,511 | +16.9% | 0.02% | +25.0% |
| Q2 2022 | $8,554,000 | +6.2% | 353,025 | +13.0% | 0.01% | +33.3% |
| Q1 2022 | $8,054,000 | -21.7% | 312,546 | -5.7% | 0.01% | -10.0% |
| Q4 2021 | $10,292,000 | +19.8% | 331,588 | -6.4% | 0.01% | +11.1% |
| Q3 2021 | $8,588,000 | – | 354,163 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |